| 摘要: |
| 呼吸道合胞病毒(简称RSV)是引起2岁以下儿童急性下呼吸道感染最常见与最重要的病原,属于国内外的研发热点。本文以抗呼吸道合胞病毒的专利申请文献为基础,对其技术发展现状、国内外专利申请态势、技术分布、重点申请人等情况进行梳理分析,表明欧美发达国家在抗呼吸道合胞病毒药物研究中处于绝对领先地位,我国近年来处于快速发展阶段。 |
| 关键词: 呼吸道合胞病毒 专利申请态势 技术分布 |
| DOI:10.13506/j.cnki.jpr.2019.03.013 |
| 基金项目: |
|
|
|
| Analysis on patented anti-respiratory syncytial virus drugs |
| MA Yongtao,SHEN Fang,ZHANG Xionghui,WANG Jingping |
| (Patent Examination Cooperation Center of the Patent Office,CNIPA,Tianjin 300304,China) |
| Abstract: |
| Respiratory syncytial virus (RSV) is the most common and most important pathogen causing acute lower respiratory tract infection in children under 2 years old. Based on the patent application literature of anti-respiratory syncytial virus. This paper sorts out the status quo of its technology development, domestic and foreign patent application situation, technology distribution, key applicants, etc. indicating that developed countries as Europe and America are absolutely leading in the research of anti-respiratory syncytial virus drugs. Status, China has been in a stage of rapid development in recent years. |
| Key words: Respiratory syncytial virus Patent application situation Technical distribution |